Ono Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	491,153	515,785	486,871	502,672	447,187	361,361
Revenue Growth	-2.48%	5.94%	-3.14%	12.41%	23.75%	16.84%
Cost of Revenue	127,170	141,716	147,950	127,126	110,062	93,511
Gross Profit	363,983	374,069	338,921	375,546	337,125	267,850
Selling, General & Admin	110,444	120,596	122,219	97,389	86,643	74,119
Research & Development	145,115	147,043	149,866	112,174	95,344	75,879
Other Operating Expenses	10,350	6,441	1,592	2,807	2,250	4,099
Operating Expenses	265,909	277,175	277,129	215,251	187,080	157,035
Operating Income	98,074	96,894	61,792	160,295	150,045	110,815
Interest Expense	-3,531	-2,212	-1,450	-125	-89	-84
Interest & Investment Income	4,353	3,458	4,631	3,574	2,403	2,349
Earnings From Equity Investments	-	-	125	1	4	-6
Currency Exchange Gain (Loss)	-	-313	-1,861	347	-723	-425
Other Non Operating Income (Expenses)	1	318	21	235	182	399
EBT Excluding Unusual Items	98,897	98,145	63,258	164,327	151,822	113,048
Gain (Loss) on Sale of Investments	-	-632	-1,730	-92	-46	-116
Gain (Loss) on Sale of Assets	-	-4,598	-214	-118	-94	-64
Asset Writedown	-	-261	-1,981	-51	-498	-316
Legal Settlements	-	-	-4	-333	-7,652	-7,527
Pretax Income	98,897	92,654	59,329	163,733	143,532	105,025
Income Tax Expense	23,936	22,743	9,163	35,694	30,619	24,340
Earnings From Continuing Operations	74,961	69,911	50,166	128,039	112,913	80,685
Minority Interest in Earnings	-353	-144	-119	-62	-190	-166
Net Income	74,608	69,767	50,047	127,977	112,723	80,519
Net Income to Common	74,608	69,767	50,047	127,977	112,723	80,519
Net Income Growth	53.85%	39.40%	-60.89%	13.53%	40.00%	6.75%
Shares Outstanding (Basic)	470	470	470	480	488	496
Shares Outstanding (Diluted)	470	470	470	480	488	497
Shares Change	0.07%	0.04%	-2.14%	-1.70%	-1.65%	-0.54%
EPS (Basic)	158.76	148.49	106.55	266.61	230.85	162.19
EPS (Diluted)	158.64	148.42	106.41	266.57	230.79	162.16
EPS Growth	53.88%	39.48%	-60.08%	15.50%	42.32%	7.33%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	127,189	130,797	77,028	106,640	154,270	56,332
Free Cash Flow Per Share	270.51	278.31	163.97	222.15	315.90	113.45
Dividend Per Share	80.000	80.000	80.000	80.000	70.000	56.000
Dividend Growth	0%	0%	0%	14.29%	25.00%	12.00%
Gross Margin	74.11%	72.52%	69.61%	74.71%	75.39%	74.12%
Operating Margin	19.97%	18.79%	12.69%	31.89%	33.55%	30.67%
Profit Margin	15.19%	13.53%	10.28%	25.46%	25.21%	22.28%
Free Cash Flow Margin	25.90%	25.36%	15.82%	21.21%	34.50%	15.59%
EBITDA	135,329	134,646	88,686	178,435	167,496	128,536
EBITDA Margin	27.55%	26.11%	18.22%	35.50%	37.45%	35.57%
D&A For EBITDA	37,255	37,752	26,894	18,140	17,451	17,721
EBIT	98,074	96,894	61,792	160,295	150,045	110,815
EBIT Margin	19.97%	18.79%	12.69%	31.89%	33.55%	30.67%
Effective Tax Rate	24.20%	24.55%	15.44%	21.80%	21.33%	23.18%
Advertising Expenses	-	32,177	30,651	24,019	17,837	11,496